Published : 15 Dec 2025
In the modern life sciences landscape, data is no longer the bottleneck; the bottleneck is synthesis. Pharmaceutical companies, specifically Health Economics and Outcomes Research (HEOR) and Real-World Evidence (RWE) teams, are drowning in an ocean of clinical literature, real-world data points, and regulatory guidelines. The traditional methods of manual extraction, often involving teams of analysts scrolling through thousands of PDFs, are becoming unsustainable. The market demands faster answers. Payers demand quicker value demonstrations. Patients demand faster access to therapies.
To meet this crushing demand, the industry has turned to technology. The integration of AI in healthcare offers a tempting promise: the ability to cut the "time-to-insight" from months to minutes. It sounds like the perfect solution. But for regulated industries, speed without safety is a liability.
We are witnessing a paradigm shift. The initial excitement over generative AI is cooling into a more pragmatic realisation: if you cannot trace the lineage of your evidence, you cannot use it. The industry is moving away from generic "black box" algorithms toward specialised, transparent systems. This is the era of Trusted AI, and it is fundamentally reshaping how evidence is generated, validated, and submitted.
In creative industries, an AI error is an amusement. In life sciences, an AI error is a compliance violation.
For HEOR, RWE, and Market Access teams, the stakes of evidence generation are incredibly high. These teams are responsible for building the value dossiers that convince Health Technology Assessment (HTA) bodies like NICE in the UK or ICER in the US that a drug is worth paying for. These submissions are scrutinised down to the decimal point.
The risks of deploying non-transparent AI in these evidence workflows are substantial. If an algorithm synthesises a conclusion regarding drug efficacy but cannot show the specific clinical trial data that supports it, the output is functionally useless for a regulatory submission. Regulatory bodies do not operate on faith; they operate on verification.
This effectively means that AI governance in pharma is becoming just as critical as the scientific data itself. Regulators are already signalling that "AI-generated" is not an excuse for "unverified." FDA and EMA guidelines are evolving to demand explainability. For these teams, verifiable insights aren't just a "nice to have"; they are the bedrock of a successful submission. Without a focus on trusted AI frameworks for life sciences systems designed with transparency, lineage, and auditability at the core, pharma companies risk rejected dossiers, delayed market access, and compromised scientific credibility.
The primary issue facing HEOR teams today is that most "off-the-shelf" AI tools were built for conversation, not for science. General-purpose Large Language Models (LLMs) are statistical prediction machines; they predict the next plausible word in a sentence. While this makes them impressive at writing emails, it makes them dangerous when analysing clinical data.
There are three specific failure points when using generic AI for high-stakes research:
1. The Provenance Gap: Traditional models struggle with sourcing. You might ask an LLM to summarise the side effects of a specific oncology treatment, and it might provide a grammatically perfect, medically accurate answer. But when you ask, "Which study is this from?" it often fails. It cannot point to the specific PDF, page number, or table row. This lack of traceability is a major hurdle for AI in healthcare adoption in serious research. You cannot submit a value dossier to a payer with a citation that says, "The AI told me so."
2.Hallucinations and Data Integrity: In a creative field, a made-up fact is a glitch. In HEOR, an AI "hallucinating" a p-value, inventing a patient cohort, or citing a non-existent paper is a data integrity failure that can derail a study. If a team builds a cost-effectiveness model based on a hallucinated efficacy number, the financial and reputational damage can be immense.
3. Inconsistency and Reproducibility: Science demands reproducibility. If you run a search query today, you should get the same results tomorrow. Generic AI models can be non-deterministic, giving different answers to the same prompt on different days. This variability is unacceptable for HTA and regulatory submissions, where the validation of AI models in healthcare depends entirely on the ability to reproduce results and audit the search strategy.
The shift toward Trusted AI is about moving from "generative" to "grounded." It changes the workflow from a mysterious black box to a transparent glasshouse.
Trusted AI ensures that every output is accurate, transparent, and, most importantly, audit-ready. It utilises a framework often referred to as RAG (Retrieval-Augmented Generation) but tailored specifically for biomedical contexts. It doesn't just "write" text based on training data; it retrieves specific documents, extracts the relevant data, and then synthesises the answer only using that retrieved data.
By specifically deploying AI for evidence generation, organisations can transform their operations:
1. Audit-Ready Outputs: Trusted AI systems provide a digital paper trail. Every claim is hyperlinked to the source. This allows for instant verification by human reviewers.
2.Automated Extraction: These systems automate the tedious extraction, synthesis, and classification of data (PICOS criteria). What used to take a junior researcher weeks of manual data entry can now be drafted in hours.
3.Human-in-the-Loop: Crucially, trusted AI does not replace the expert; it augments them. It highlights relevant text and suggests data points, but the human expert makes the final validation. This drastically reduces the manual workload for HEOR and RWE teams, allowing researchers to focus on strategy and analysis rather than data scrubbing.
This approach effectively solves the difficult problem of how pharma teams ensure AI accuracy and compliance by keeping the human expert in control while delegating the grunt work to the machine.
This is where Pienomial separates itself from the generic AI crowd. We recognised early on that the life sciences industry didn't need a better chatbot; it needed a better research assistant. We aren't just wrapping ChatGPT in a new interface; we are building infrastructure for AI for evidence generation.
The Knolens Suite is designed to address the specific pain points of the evidence lifecycle:
1.100% Traceability: We believe in zero-trust verification. Within the Knolens Suite, every insight generated is linked back to its source document. You can click through from the extracted data point directly to the original PDF sentence or table. This "click-to-verify" functionality turns a black box into a verifiable audit trail.
2.Schema-Based Normalisation: In life sciences, semantics matter. "Heart failure" in one study might be "Cardiac insufficiency" in another. Generic AI misses these nuances. Our platform utilises schema-based ontology normalisation, aligning data with global standards like MeSH (Medical Subject Headings) and CTCAE (Common Terminology Criteria for Adverse Events). This ensures that data isn't just extracted; it is structured, standardised, and ready for analysis.
3.Purpose-Built Models: We do not rely solely on generalist models. Our proprietary AI models are trained specifically for the nuances of AI in healthcare, avoiding the generic errors common in broader tools. Our systems understand the structure of a clinical trial, the hierarchy of evidence, and the importance of statistical significance.
The adoption of these trusted frameworks is having a measurable impact on the industry. It is no longer a theoretical exercise; it is an operational reality.
1. Faster Insights and Market Access Time is the most valuable currency in pharma. By using specialised AI for evidence generation tools, teams can accelerate the production of Systematic Literature Reviews (SLRs) and value dossiers. This means faster submissions to payers, faster feedback loops, and ultimately, faster patient access to life-saving therapies.
2. Risk Mitigation through Governance The result of using trusted systems is a tangible reduction in compliance risks. When you remove the doubt surrounding your data through rigorous AI governance in pharma, you build a defensive wall around your evidence. If a regulator asks, "Where did this number come from?", your team has the answer immediately available.
3. Strategic Confidence Perhaps the most significant impact is cultural. When teams trust their tools, they move with more confidence. The ongoing validation of AI models in healthcare workflows ensures that the system is constantly checked against human benchmarks. This builds stronger confidence in evidence-driven decisions, both internally among stakeholders who decide on pipeline investments and externally with the payers who decide on reimbursement.
The life sciences industry is reaching a tipping point. The volume of medical knowledge is doubling every few months, and manual methods can no longer keep pace. The question is no longer if AI in healthcare will be used in evidence generation, but how it can be trusted.
We are moving past the "hype cycle" of AI and entering the "value cycle." In this new phase, the tools that win will not be the ones that can write the most creative poetry, but the ones that can provide the most accurate, traceable, and scientifically valid data. The shift toward transparent, explainable AI for evidence generation is the only path forward for regulated environments.
If your HEOR or RWE team is still relying on manual extraction or wary of "black box" tools, it is time to re-evaluate your infrastructure. Evidence is the currency of pharma; ensure yours is counterfeit-proof.
Don't let AI hallucinations derail your launch. Switch to the schema-based, transparent AI engine with Pienomial built specifically for Life Sciences. Get Your Demo Today
1. What distinguishes "Trusted AI" from standard generative AI tools like ChatGPT in the context of life sciences?
While general-purpose Large Language Models (LLMs) function as statistical prediction machines designed for conversation, Trusted AI acts as a transparent research assistant built for science. The key difference lies in "grounding." Standard tools often operate as "black boxes" that can hallucinate facts or fail to cite sources. Trusted AI, conversely, operates as a "glasshouse"; it utilises Retrieval-Augmented Generation (RAG) to ensure every output is derived strictly from retrieved documents, offering 100% traceability rather than creative prediction.
2. How does Trusted AI mitigate compliance risks for HEOR and Market Access submissions?
In regulated environments, "AI-generated" cannot mean "unverified." Trusted AI mitigates risk by eliminating the "provenance gap." For every claim or data point synthesised in a value dossier, Trusted AI systems provide a digital paper trail (lineage) that hyperlinks directly to the source PDF, page number, or table row. This ensures that submissions to HTA bodies (like NICE or ICER) are audit-ready, allowing teams to instantly verify data origins if challenged by regulators.
3. Does adopting Trusted AI in evidence generation replace the need for human experts and analysts?
No, Trusted AI is designed to augment human expertise, not replace it. The article emphasises a "Human-in-the-Loop" approach. The AI handles the "grunt work", automating the tedious extraction, synthesis, and classification of clinical literature, which allows HEOR and RWE teams to focus on high-level strategy, analysis, and final validation. It shifts the researcher's role from data scrubbing to strategic decision-making.
4. Why is "schema-based normalisation" critical for evidence synthesis, and how does it differ from generic extraction?
Generic AI often misses semantic nuances, failing to realise that "Heart failure" in one study might be labelled "Cardiac insufficiency" in another. Schema-based normalisation aligns extracted data with global standards like MeSH (Medical Subject Headings) and CTCAE. This ensures that data is not just "read" by the AI, but structured and standardised, making it analytically useful and consistent across different studies for Systematic Literature Reviews (SLRs).
5. How does Trusted AI address the "hallucination" issues common in AI, such as inventing p-values or patient cohorts?
Trusted AI moves away from the non-deterministic nature of creative LLMs. By using specialised biomedical models and a "zero-trust verification" framework, systems like the Knolens Suite ensure that the AI only synthesises answers using data it has actually retrieved and indexed. If the AI cannot trace a specific clinical trial data point back to a verifiable source, it does not invent one, thereby preventing the data integrity failures that can derail cost-effectiveness models.
